Tagged with Sanofi

Brazil When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature sensitive biologicals, one understands the urgent need to develop solutions guaranteeing appropriate transport conditions in Brazil. “We may be vaguely…

Poland Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way. Moreover, she highlights the importance of achieving reimbursement for three key products for Multiple Sclerosis and Oncology as well as…

Brazil Pius Hornstein, MSc, PhD, country chair Sanofi Brazil and general manager Pharma, shares his positive outlook on the Brazilian pharma market over the next few years and details Sanofi’s strategy in Brazil; a ‘must-win’ market for the company. Unsatisfied with being just the top-ranked multinational pharma company in Brazil, he…

Ukraine The Top 30 companies in Ukraine based on 2016 sales. Homegrown hero Farmak leads the way, with USD 88 million in sales for the year. French company Sanofi follows in second place.

Tunisia Chokri Jeribi, country chair of Sanofi Tunisia since 2016, is responsible for the development and market leadership hold of Sanofi’s affiliate in Tunisia. In this interview he stresses the importance that clinical trials activities for both the company and the country. Additionally, Jeribi documents the unique collaboration system with local…

Colombia The top 20 pharma companies in the Colombian retail market by market share. US-headquartered Abbott leads the way with 13.3%, followed by French outfit Sanofi with 8.7% and domestic champion Tecnoquimicas in third place with 8.5%. Click here to download the Healthcare & Life Sciences Review Colombia 2017

Bulgaria Jeroen Weites, South-East Europe Cluster head General Medicines and country chair Bulgaria at Sanofi, gives an overview of the company’s leadership in the country and highlights the urgency of developing a healthcare masterplan beyond any political mandate to ensure the sustainability as well as predictability of the Bulgarian healthcare system.…

Tunisia Diabetes is an important problem in Tunisia, with prevalence is expected to increase over the coming years. Jean-Francois Courtet, general manager of Novo Nordisk in Tunisia, points out rgar “diabetes is the second largest cause of death in Tunisia”. Moez Lindhallah Mokadem, director of Pharmacie Centrale de Tunisie (PCT), adds…

Canada Peter Brenders, general manager of Sanofi Genzyme Canada, highlights the strategic significance of the Canadian affiliate, which has seen double-digit growth every quarter for the past five and a half years; the challenges it faces within Canada’s market access environment; and the personal motivation driving him after three decades in…

Canada Niven Al-Khoury, President of Sanofi Canada, highlights the strong presence that Sanofi has established in the country over the past 100 years, some of the notable historical achievements from collaboration between Sanofi and Canadian science, as well as the value that Sanofi is committed to bringing to the Canadian healthcare…

Indonesia Benoit Martineau, President Director at Sanofi Indonesia, explains the transformation of the Indonesian affiliate and reaffirms the strong commitment of Sanofi in helping the Indonesian government to successfully implement their patient access roadmap. Mr. Martineau, could you please introduce yourself to our international audience as well as your main areas…

Greece In terms of value, global giants Pfizer, Novartis and Sanofi lead the way in Greece. Click here to see more facts and figures from Greece